Menopause Hormone Therapy (HRT) in Sparks, NV

Bioidentical hormones in Sparks: what it means

"Bioidentical" describes a hormone whose chemical structure matches one the body makes. Estradiol and micronized progesterone are both bioidentical: their structure matches the hormones the ovaries make. FDA-approved versions of both are sold by prescription at retail pharmacies.

Only 2 OB-GYNs list a primary practice address in Sparks in the NPI registry. For 109,106 residents that is 1.8 per 100,000, under the US 17.8 and below Nevada's 13.8. That is about 6,440 women aged 45 to 64 for each OB-GYN in the city, a ratio rather than a count of open appointments.

Widen the circle and the count grows: 56 in the city or within 10 miles, 88 within 25 miles. For the 516,083 people who live within 25 miles, that is 17.1 per 100,000. Whether or not you have an OB-GYN, you can ask a physician licensed in Nevada about menopause hormone therapy online from Sparks, with no waiting room.

"BHRT" often means compounded hormones, a cream, a blend such as Bi-Est or a pellet that a pharmacy mixes for one prescription. They are not FDA-approved, which means the FDA cannot assure their safety or effectiveness. The FDA also says it has no evidence that they are safe and effective, or more effective than approved hormone therapy. A 2020 National Academies review found no rigorous evidence of their safety and effectiveness.

For women in Sparks, a physician licensed in Nevada can prescribe estradiol (pill, patch, cream or vaginal) and progesterone when they fit your history. There are no pellets. Because the dispensing pharmacy also compounds, you can ask whether your estradiol or progesterone is an FDA-approved product. Two options are compounded for certain: testosterone cream for women and Bi-Est are not FDA-approved.

A pellet clinic is a different model: it implants a hormone pellet under the skin during a visit, and compounded pellets are not FDA-approved. The Endocrine Society points to a study that found hormone levels well above the expected range in women using them. ACOG recommends FDA-approved menopause hormone therapy over compounded hormones.

Sources: FDA: Menopause · FDA: National Academies study of compounded bioidentical hormones (2020) · Endocrine Society position statement on compounded bioidentical hormones (2019) · ACOG Clinical Consensus No. 6, compounded bioidentical menopausal hormone therapy (2023) · CMS NPPES NPI full file, 2026-10-11